Edition:
United States

Cardiome Pharma Corp (CRME.OQ)

CRME.OQ on NASDAQ Stock Exchange Capital Market

3.04USD
23 Mar 2017
Change (% chg)

$-0.01 (-0.33%)
Prev Close
$3.05
Open
$3.07
Day's High
$3.09
Day's Low
$3.04
Volume
5,501
Avg. Vol
13,768
52-wk High
$6.29
52-wk Low
$2.35

CRME.OQ

Chart for CRME.OQ

About

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company's segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS... (more)

Overall

Beta: 1.41
Market Cap(Mil.): $95.82
Shares Outstanding(Mil.): 31.90
Dividend: --
Yield (%): --

Financials

  CRME.OQ Industry Sector
P/E (TTM): -- 28.87 29.63
EPS (TTM): -0.79 -- --
ROI: -45.07 13.48 13.01
ROE: -72.72 14.39 14.16

BRIEF-Cardiome receives Notice of Compliance from Health Canada for its BRINAVESS NDS

* Cardiome receives notice of compliance from Health Canada for its BRINAVESS NDS

Mar 14 2017

BRIEF-Cardiome Pharma Corp says Q4 loss per share $0.18

* Cardiome reports fourth quarter and full year 2016 financial results

Mar 07 2017

BRIEF-Cardiome announces commercial launch of Xydalba(dalbavancin) in France

* Cardiome Pharma Corp - received authorization from French transparency pricing commission to begin selling Xydalba in France

Mar 03 2017

BRIEF-Cardiome pharma says it has moved closer to launching Xydalba in UK

* Cardiome pharma says it has moved one step closer to launching Xydalba in UK by receiving an established price from secretary of state for health

Nov 29 2016

BRIEF-Cardiome Q3 loss per share $0.19

* Remain on track to meet expectations for 2016 revenues in mid $20 million

Nov 07 2016

BRIEF-Cardiome Pharma initiates commercial sales operations in Canada

* Cardiome Pharma Corp - has initiated commercial sales operations in Canada

Oct 14 2016

More From Around the Web

Earnings vs. Estimates